Citations

Mayo Clinic

Showing 10 of 108523 citations.

Safe transition to surgery: working differently to make blood transfusion process safer for elective surgery
Badjie, Karafa S., Rogers, James C., Jenkins, Sarah M. , Bundy, Kevin L., Stubbs, James R. , Badjie, Karafa S W, Rogers, James C., Cima, Robert R.

Transfusion | April 9, 2015 | Volume: 55 | Issue: 9 | Pages: 2238-2245

10.1111/trf.13108 | PMID 25854123 Get It

BACKGROUNDOur institutional policy allows patients who are scheduled for elective surgery with no history of a pregnancy or blood transfusion in the preceding 3 months to have a presurgical sample (PSS) collected and tested up to 56 days before their scheduled surgery; however, our PSS TS completion rate in eligible patients before the morning of surgery was 83%. In 2011, a team was charged to develop a standardized process along with other process improvements while ensuring no increase in transfusion‐related events.STUDY DESIGN AND METHODSThe team followed the DMAIC framework in appraising the effectiveness and efficiency of the current state process including baseline data collection such as PSS TS completion rate, number of eligible patients needing a PSS TS on the day of surgery, benchmarking, SSBO utilization, and future state mapping.RESULTSFirst quarter (Q1) 2011 versus Q1 2012 postimplementation results showed significant improvements of the process including a 53% decrease in PSS TS on the day of surgery; a 13% increase in PSS TS completion before the morning of surgery; a 26% reduction in total XM RBCs; and a 58.8% reduction in XM RBCs not issued, plus a 47% decrease in RBC wastage. Q1 2011 versus Q1 2013 showed a 41% reduction in total XM RBCs and an 88.4% reduction in XM RBCs not issued but overall RBCs issued versus returned increased slightly and represents a future opportunity for improvement.CONCLUSIONSThe redesigned, transformational process eliminated SSBO and improved ordering process and PSS TS completion rate as well as blood product ordering and utilization.
Impact of persistent minimal residual disease post‐consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report
Shiramizu, Bruce , Goldman, Stanton, Agsalda‐Garcia, Melissa, Galardy, Paul J. , Perkins, Sherrie L., Frazer, J. Kimble , Sanger, Warren G., Anderson, James R. , Gross, Thomas G. , Weinstein, Howard J., Harrison, Lauren , Barth, Matthew J. , Mussolin, Lara , Cairo, Mitchell S. , Galardy, Paul, Smith, Lynette M.

British Journal of Haematology | April 9, 2015 | Volume: 170 | Issue: 3 | Pages: 367-371

10.1111/bjh.13443 | PMID 25858645 Get It

SummaryPatient‐specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French‐British‐American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real‐time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD‐positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.
Acquired factor V deficiency in myeloproliferative neoplasms: a Mayo Clinic series of 33 patients
Ashrani, Aneel A. , Tefferi, Ayalew , Pruthi, Rajiv K. , Pardanani, Animesh

British Journal of Haematology | April 9, 2015 | Volume: 171 | Issue: 5 | Pages: 875-879

10.1111/bjh.13438 | PMID 25854415 Get It

Effect of Tricuspid Regurgitation and the Right Heart on Survival After Transcatheter Aortic Valve Replacement
Lindman, Brian R. , Maniar, Hersh S., Lerakis, Stamatios , Mack, Michael J. , Suri, Rakesh M. , Thourani, Vinod H. , Babaliaros, Vasilis , Kereiakes, Dean J. , Miller, D. Craig , Tuzcu, E. Murat , Svensson, Lars G. , Xu, Ke , Doshi, Darshan , Leon, Martin B. , Zajarías, Alan , Jaber, Wael A. , Whisenant, Brian, Whisenant, Brian K. , Lindman, Brian R

Circulation: Cardiovascular Interventions | April 9, 2015 | Volume: 8 | Issue: 4 | Pages: No page available

10.1161/circinterventions.114.002073 | PMID 25855679 Get It

Background— Tricuspid regurgitation (TR) and right ventricular (RV) dysfunction adversely affect outcomes in patients with heart failure or mitral valve disease, but their impact on outcomes in patients with aortic stenosis treated with transcatheter aortic valve replacement has not been well characterized. Methods and Results— Among 542 patients with symptomatic aortic stenosis treated in the Placement of Aortic Transcatheter Valves (PARTNER) II trial (inoperable cohort) with a Sapien or Sapien XT valve via a transfemoral approach, baseline TR severity, right atrial and RV size and RV function were evaluated by echocardiography according to established guidelines. One-year mortality was 16.9%, 17.2%, 32.6%, and 61.1% for patients with no/trace (n=167), mild (n=205), moderate (n=117), and severe (n=18) TR, respectively ( P <0.001). Increasing severity of RV dysfunction as well as right atrial and RV enlargement were also associated with increased mortality ( P <0.001). After multivariable adjustment, severe TR (hazard ratio, 3.20; 95% confidence interval, 1.50–6.82; P =0.003) and moderate TR (hazard ratio, 1.60; 95% confidence interval, 1.02–2.52; P =0.042) remained associated with increased mortality as did right atrial and RV enlargement, but not RV dysfunction. There was an interaction between TR and mitral regurgitation severity ( P =0.04); the increased hazard of death associated with moderate/severe TR only occurred in those with no/trace/mild mitral regurgitation. Conclusions— In inoperable patients treated with transcatheter aortic valve replacement, moderate or severe TR and right heart enlargement are independently associated with increased 1-year mortality; however, the association between moderate or severe TR and an increased hazard of death was only found in those with minimal mitral regurgitation at baseline. These findings may improve our assessment of anticipated benefit from transcatheter aortic valve replacement and support the need for future studies on TR and the right heart, including whether concomitant treatment of TR in operable but high-risk patients with aortic stenosis is warranted. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01314313.
Risk and protective factors for cognitive impairment in persons aged 85 years and older
Roberts, Rosebud O., Cha, Ruth H., Mielke, Michelle M. , Geda, Yonas E. , Petersen, Ronald C. , Cha, Ruth H., Boeve, Bradley F. , Machulda, Mary M. , Knopman, David S. , Mielke, Michelle M , Geda, Yonas E

Neurology | April 9, 2015 | Volume: 84 | Issue: 18 | Pages: 1854-1861

10.1212/wnl.0000000000001537 | PMID 25854867 Get It

T-cell Expression of IL10 Is Essential for Tumor Immune Surveillance in the Small Intestine
Dennis, Kristen L., Blatner, Nichole R., Wang, Shuya , Venkateswaran, Vysak, Gounari, Fotini , Cheroutre, Hilde , Roers, Axel , Egilmez, Nejat K. , Khazaie, Khashayarsha , Saadalla, Abdulrahman , Weaver, Casey T. , Gounari, Fotini

Cancer Immunology Research | April 8, 2015 | Volume: 3 | Issue: 7 | Pages: 806-814

10.1158/2326-6066.cir-14-0169 | PMID 25855122 Get It

Abstract IL10 is attributed with immune-suppressive and anti-inflammatory properties, which could promote or suppress cancer in the gastrointestinal tract. Loss of IL10 exacerbates colonic inflammation, leading to colitis and cancer. Consistent with this, transfer of IL10-competent regulatory T cells (Treg) into mice with colitis or hereditary polyposis protects against disease, while IL10-deficient mice are predisposed to polyposis with increased colon polyp load. Little is known about the protective or pathogenic function of IL10 in cancers of the small intestine. We found CD4+ T cells and CD4+ Foxp3+ Tregs to be the major sources of IL10 in the small intestine and responsible for the increase in IL10 during polyposis in the APCΔ468 mouse model of hereditary polyposis. Targeted ablation of IL10 in T cells caused severe IL10 deficiency and delayed polyp growth. However, these polyps progressively lost cytotoxic activity and eventually progressed to cancer. Several observations suggested that the effect was due to the loss of IFNγ-dependent immune surveillance. IL10-incompetent CD4+ T cells failed to secrete IFNγ when stimulated with polyp antigens and were inefficient in T-helper-1 (TH1) commitment. By contrast, the TH17 commitment was unaffected. These findings were validated using mice whose T cells overexpress IL10. In these mice, we observed high intra-polyp cytotoxic activity and attenuation of polyposis. Thus, expression of IL10 by T cells is protective and required for immune surveillance in the small intestine. Cancer Immunol Res; 3(7); 806–14. ©2015 AACR.
Tumor necrosis factor‐α and its role as a mediator in myocardial infarction: A brief review
Tian, Ming , Yuan, Yun‐Chuan, Huang, Rongchong, Gionfriddo, Michael R. , Li, Jiayi

Chronic Diseases and Translational Medicine | April 8, 2015 | Volume: 1 | Issue: 1 | Pages: 18-26

10.1016/j.cdtm.2015.02.002 | PMID 29062983 Get It

AbstractTumor necrosis factor‐α (TNF‐α) contributes to myocardial infarction (MI) injury. Polymorphism of TNF‐α gene promoter region and secretion and release of TNF‐α and its transformation by a series of signaling pathways are all changed at different points of pathophysiological process in MI. Researches also investigated TNF‐α antagonists and their potential therapeutic role in the setting of MI and heart failure at both molecular and clinical level. This article briefly reviews TNF‐α and its mechanism as a mediator in MI.
Timely Surgical Follow-up for Melanoma Among Medicare Beneficiaries
Brewer, Jerry D., Lin, Elaine P.

JAMA Dermatology | April 8, 2015 | Volume: 151 | Issue: 7 | Pages: 741

10.1001/jamadermatol.2015.0559 | PMID 25853574 Get It

Reversal of Neuromuscular Blockade
Brull, Sorin J. , Prielipp, Richard C., Brull, Sorin J

Anesthesiology | April 8, 2015 | Volume: 122 | Issue: 6 | Pages: 1183-1185

10.1097/aln.0000000000000675 | PMID 25856292 Get It